RECURRENT LUNG NON-SQUAMOUS NON-SMALL CELL CARCINOMA
Clinical trials for RECURRENT LUNG NON-SQUAMOUS NON-SMALL CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT LUNG NON-SQUAMOUS NON-SMALL CELL CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT LUNG NON-SQUAMOUS NON-SMALL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo shows promise in Tough-to-Treat lung cancer
Disease control OngoingThis study tests two experimental treatments—cabozantinib alone or combined with nivolumab—against standard chemotherapy for people with advanced non-squamous non-small cell lung cancer that has come back. About 117 adults with stage IV disease are taking part. The goal is to see…
Matched conditions: RECURRENT LUNG NON-SQUAMOUS NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 07:59 UTC
-
New targeted drug shows promise for Hard-to-Treat lung cancer
Disease control OngoingThis study tests a drug called AMG 510 in people with advanced lung cancer that has a specific genetic change (KRAS G12C). The drug targets this change to stop cancer growth. About 116 participants will receive the treatment to see if it shrinks tumors and how safe it is.
Matched conditions: RECURRENT LUNG NON-SQUAMOUS NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Apr 29, 2026 15:04 UTC